Navigation Links
Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results

BETHESDA, Md., March 13 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focusing on the development of novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced its financial results for the fourth quarter and the full year ended December 31, 2007. As a result of the reverse merger between Micromet AG and CancerVax Corporation that was completed on May 5, 2006, the financial information included below for the fiscal year 2006 consists of Micromet AG's historical financial results for the period of January 1, 2006 to May 5, 2006 without the inclusion of the financial results of CancerVax, and the combined results of the two companies thereafter.

Summary of Recent Events:

-- Micromet published data on its BiTE(R) antibody MT103 at the annual

meeting of the American Society of Hematology in December, showing that

MT103 induces dose-dependent objective complete and partial responses

in late stage lymphoma patients. The BiTE antibody could also clear the

bone marrow and other infiltrated organs from tumor cells. Particularly

encouraging was the observation of complete responses in patients with

mantle cell lymphoma (MCL) -- a disease that is difficult to treat. In

Europe, Micromet has initiated a phase 2 study in acute lymphoblastic

leukemia, one of the most aggressive blood cancers.

-- Micromet has completed preclinical development for its second BiTE

antibody MT110. MT110 binds to EpCAM, a cell surface molecule that is

highly expressed on many solid tumors and on cancer stem cells -- those

cancer cells responsible for metastasis and resistance of tumors to


-- In 2007, Micromet partnered two of its earlier stage programs. The

company is collaborating with Nycomed on the development of MT203, a

human antibody that neutralizes GM-CSF, a key cytokine involved in

autoimmune diseases and chronic inflammation. In addition, Micromet

has licensed MT293 to TRACON Pharmaceuticals, Inc. MT293 is an

anti-angiogenic antibody that aims to limit tumor growth by preventing

blood vessels to reach the tumor. TRACON initiated a phase 1 clinical

trial in July 2007.

-- In June 2007, Micromet closed a $25 million PIPE transaction, adding to

its shareholder base a number of experienced U.S.-based biotech funds.

Several of Micromet's existing shareholders participated in this

financing round.

Summarizing the events, Christian Itin, Ph.D., President and Chief Executive Officer of Micromet said: "In 2007, we have made significant progress with our BiTE antibodies demonstrating strong clinical activity for MT103 in late-stage non-Hodgkin's lymphoma patients and completing preclinical development of MT110, our first BiTE antibody targeting solid tumors. In 2008, we will broaden the clinical program for MT103 and initiate a first clinical trial for MT110. We will also advance our earlier-stage BiTE antibodies and report on results at clinical and scientific conferences. In addition, we expect to start a phase 2 clinical trial with adecatumumab (MT201) in adjuvant disease in the second half of 2008. Finally, we will continue to explore opportunities for new collaborations in 2008."

Financial Results:

Quarter Ended December 31, 2007

For the three months ended December 31, 2007, Micromet recognized revenues of $7.0 million, compared to $13.8 million for the same period in 2006. Included in 2006 revenues was the receipt of a $10.0 million milestone payment from Merck Serono following the completion of two phase 2 clinical trials for adecatumumab. Total operating expenses were $13.1 million for the three months ended December 31, 2007, compared to $10.9 million for the same period in 2006. For the three months ended December 31, 2007, Micromet reported a net loss of $3.8 million, or $0.09 per basic and diluted share, compared to net income of $3.4 million, or $0.11 per basic and diluted share, for the same period in 2006. The positive net income in 2006 was due primarily to the milestone payment received from Merck Serono.

Year Ended December 31, 2007

Revenues for the year ended December 31, 2007 were $18.4 million, compared to $27.6 million for 2006. For the year ended December 31, 2007, Micromet reported operating expenses of $43.6 million, compared to $61.2 million for the same period in 2006. In connection with the merger with CancerVax, Micromet recorded a non-recurring, non-cash charge of $20.9 million in the second quarter of 2006 due to the immediate write-off of CancerVax's in- process research and development programs. For the year ended December 31, 2007, net loss was $20.1 million, or $0.55 per basic and diluted share, compared to $34.0 million, or $1.29 per basic and diluted share, for 2006.

Micromet's cash and cash equivalents were $27.1 million as of December 31, 2007. Net cash used in operating activities was $14.3 million for the year ended December 31, 2007 and $15.4 million in 2006. Based on the status of our development programs, management believes that the cash balance at December 31, 2007 is sufficient to fund operations into the second quarter of 2009.

2008 Outlook:

-- Micromet will present an update on its proprietary BiTE antibody

technology platform and new BiTE antibody programs at the conference of

the American Association of Cancer Research (AACR) in April 2008.

-- A phase 1/2 clinical trial evaluating MT103 in patients with chronic

lymphocytic leukemia is expected to be started in the United States by

Micromet's collaboration partner MedImmune. In addition, at the

conference of the American Society of Hematology (ASH) in December 2008,

Micromet anticipates that it will provide an update on the clinical

data of the ongoing clinical trials with MT103.

-- Micromet expects to initiate dosing of patients in a phase 1 clinical

trial of MT110 in patients with solid tumors in the first half of 2008.

-- Micromet is currently developing the study design for a clinical trial

to evaluate adecatumumab (MT201) in an adjuvant setting and plans to

initiate this clinical trial in the second half of 2008. In addition,

data of the ongoing phase 1b combination trial with docetaxel are

expected to be presented in the second half of 2008.

-- Micromet expects to initiate IND-enabling studies with MT203 as part of

its collaboration with Nycomed.

Conference Call and Audio Webcast Today, March 13, 2007, at 9:00am Eastern Time

To participate in this conference call, dial 800-561-2813 (U.S.) or 617-614-3529 (international), passcode: 29595857. The audio webcast can be accessed at: in the investor relations section of the website.

A replay of the call will be available from 11:00 am Eastern Time on March 13, 2008 (4:00 pm Central European Time) through Thursday, March 20, 2008. The replay number is 888-286-8010 (U.S.) or 617-801-6888 (international), passcode: 40638317.

About Micromet, Inc. (

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Three of its antibodies are currently in clinical trials, while the remainder of the product pipeline is in preclinical development. The BiTE(R) antibody MT103 is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. BiTE antibodies represent a new class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful "killer cells" of the human immune system, to eliminate cancer cells. Micromet is developing MT103 in collaboration with MedImmune, Inc., a subsidiary of AstraZeneca plc. The second clinical stage antibody is adecatumumab, also known as MT201, a human monoclonal antibody which targets epithelial cell adhesion molecule (EpCAM)-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. The third clinical stage antibody, MT293 is licensed to TRACON Pharmaceuticals, Inc. and is being developed in a phase 1 clinical trial for the treatment of patients with cancer. In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding the efficacy, safety, and intended utilization of Micromet's product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research, discovery of new product candidates, and clinical trials, and plans regarding partnering and outlicensing activities and the participation at upcoming scientific conferences. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety or efficacy in larger- scale or later clinical trials, the risk that the Company will not obtain approval to market its products, the risks associated with reliance on outside financing to meet capital requirements, the risks associated with reliance on collaborative partners for future revenues under the terms of its existing collaboration agreements, the risks associated with further clinical trials, development and commercialization of product candidates, and the risks associated with recruiting and retention of individuals in key management functions. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. These factors and others are more fully discussed in Micromet's periodic reports and other filings with the SEC, including the "Risk Factors" sections of such reports.

Any forward-looking statements are made pursuant to Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and, as such, speak only as of the date made. Micromet undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Micromet, Inc.

Condensed Consolidated Balance Sheets

(In thousands, except par value)

December 31, December 31,

2007 2006


Current assets:

Cash and cash equivalents $27,066 $24,301

Accounts receivable 4,689 2,319

Prepaid expenses and other current assets 2,579 2,048

Total current assets 34,334 28,668

Property and equipment, net 4,390 3,357

Goodwill 6,462 6,917

Patents, net 7,680 8,850

Other assets 196 321

Restricted cash 3,190 3,059

Total assets $56,252 $51,172

Liabilities and Stockholders' Equity

Current liabilities:

Accounts payable $2,335 $1,680

Accrued expenses 4,765 10,153

Warrant liabilities 5,218 -

Other liabilities 520 366

Short-term note - 1,320

Current portion of long-term debt obligations 2,401 599

Current portion of deferred revenue 3,360 2,972

Total current liabilities 18,599 17,090

Deferred revenue, net of current portion 8,366 195

Other non-current liabilities 2,055 1,961

Long-term debt obligations, net of current

portion 2,254 7,408


Stockholders' equity:

Preferred stock, $0.00004 par value;

10,000 shares authorized; no shares issued

and outstanding - -

Common stock, $0.00004 par value; 150,000

shares authorized; 40,778 and 31,419 shares

issued and outstanding at December 31,

2007 and December 31, 2006, respectively 2 1

Additional paid-in capital 184,014 163,482

Stock subscription receivables - (27)

Accumulated other comprehensive income 5,895 5,869

Accumulated deficit (164,933) (144,807)

Total stockholders equity 24,978 24,518

Total liabilities and stockholders' equity $56,252 $51,172

Micromet, Inc.

Condensed Consolidated Statements of Operations

(In thousands, except per share amounts)

Three Months Ended Year Ended

December 31, December 31,

2007 2006 2007 2006


Collaboration agreements $6,751 $12,596 $17,366 $25,449

License fees and other 234 1,211 1,018 2,134

Total revenues 6,985 13,807 18,384 27,583

Operating expenses

Research and development 9,471 7,385 29,191 28,252

In-process research and

development - - - 20,890

General and administrative 3,590 3,495 14,430 12,012

Total operating expenses 13,061 10,880 43,621 61,154

Income (loss) from operations (6,076) 2,927 (25,237) (33,571)

Other income (expense)

Interest income (expense) 419 (32) 429 (982)

Change in fair value of

warrants 41 - 1,750 -

Other income (expense), net 1,817 500 2,932 561

Net income (loss) attributable

to common stockholders $(3,799) $3,395 $(20,126) $(33,992)

Basic net income (loss) per

common share $(0.09) $0.11 $(0.55) $(1.29)

Diluted net income (loss) per

common share $(0.09) $0.11 $(0.55) $(1.29)

Weighted average shares used

to compute basic diluted net

income (loss) per share 40,757 31,416 36,362 26,366

Weighted average shares used to

compute diluted net income

(loss) per share 40,757 31,966 36,362 26,366

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
2. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
3. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
4. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
5. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
6. Helix BioPharma reports Q2 2008 highlights, financial results
7. Oncothyreon reports full year and fourth quarter 2007 financial results
8. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
9. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
10. ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
11. Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
Post Your Comments:
(Date:11/30/2015)... , ... November 30, 2015 , ... Global Stem Cells Group announced the ... in the cities of Arica and Iquique in northern Chile. The facilities are part of ... the most advanced protocols and techniques in stem cell medicine to patients from around the ...
(Date:11/30/2015)... Mass. , Nov. 30, 2015 ... HART ), a biotechnology company developing bioengineered organ ... received written notification from The NASDAQ Stock Market ... bid price requirements. The letter noted that as ... HART,s common stock having exceeded $1.00 per share ...
(Date:11/30/2015)... Nov. 30, 2015 Human Longevity, Inc. (HLI), ... has acquired Cypher Genomics, Inc., a leading genome informatics ... interpretation software solutions. The San Diego ... including Cypher CEO and Co-founder, Ashley Van Zeeland , ... Business.  Financial details of the deal were not disclosed. ...
(Date:11/30/2015)... Germany , November 30, 2015 ... Vienna, Austria to be held December 1-4, ... in Vienna, Austria to be ... owned subsidiary of Vycor Medical, Inc. ("Vycor") (OTCQB: VYCO), announced ... Therapy Suite at the 3rd European Congress of NeuroRehabilitation ...
Breaking Biology Technology:
(Date:11/4/2015)... ALBANY, New York , November 4, 2015 /PRNewswire/ ... According to a new market report published by Transparency ... Size, Share, Growth, Trends and Forecast 2015 - 2022", ... value of US$ 30.3 bn by 2022. The market ... during the forecast period from 2015 to 2022. Rising ...
(Date:10/29/2015)... RESTON, Va. , Oct. 29, 2015 ... announced today that it has released a new version ... Daon customers in North America ... gains. IdentityX v4.0 also includes a FIDO UAF ... customers are already preparing to activate FIDO features. These ...
(Date:10/29/2015)... 2015 Today, LifeBEAM , a ... 2XU, a global leader in technical performance sports ... with advanced bio-sensing technology. The hat will allow ... key biometrics to improve overall training performance. As ... will bring together the most advanced technology, extensive ...
Breaking Biology News(10 mins):